Malignant Mesothelioma Market Growth Supported by Key Drivers, Expected to Hit $3.32 Billion by 2029
Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
What Are the Key Growth Indicators and Market Expansion Estimates for the Malignant Mesothelioma Market Through 2029?
The malignant mesothelioma market size has grown strongly in recent years. It will grow from $2.46 billion in 2024 to $2.61 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increasing investments in oncology research, rise in asbestos-related litigation cases, rise in hospital investments, rise in the aging population, and grow in ai-driven drug discovery platforms.
The malignant mesothelioma market size is expected to see strong growth in the next few years. It will grow to " $3.32 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to growing adoption of immunotherapy treatments, increasing focus on personalized medicine, rising utilization of minimally invasive surgical procedures, rising healthcare expenditure, and growing number of clinical trials. Major trends in the forecast period include advancements in immunotherapy, personalized medicine, early detection initiatives, minimally invasive surgical techniques, and regulatory approvals.
Get your free report sample today:
Which Core Market Drivers Are Influencing the Development of the Malignant Mesothelioma Market?
The increasing clinical research and development efforts are expected to drive the growth of the malignant mesothelioma market going forward. Clinical research and development (R&D) efforts involve conducting scientific studies and trials to develop new drugs, treatments, and medical devices. These efforts include testing new products' safety, efficacy, and potential side effects through controlled clinical trials. The increasing clinical research and development efforts are due to the growing demand for new and improved treatments, especially with the rising prevalence of chronic diseases and complex conditions. Research and development efforts drive malignant mesothelioma by accelerating advances in diagnostics, treatments, and targeted therapies, fostering innovative approaches to improve early detection, enhance survival rates, and develop more effective, less invasive treatment options. For instance, in January 2025, according to Anadolu Agency, a Turkey-based state-run news agency, clinical trials make up nearly 40% of the U.S. pharmaceutical research budget, totaling approximately $7 billion annually. Therefore, the increasing research and development efforts are driving the growth of the malignant mesothelioma market.
How Is the Malignant Mesothelioma Market Structured Across Its Key Segment Categories?
The malignant mesotheliomamarket covered in this report is segmented –
1) By Treatment Type: Chemotherapy; Radiation Therapy; Surgery; Immunotherapy; Targeted Therapy
2) By Route Of Administration: Oral; Intravenous; Injectable; Topical
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies
4) By End-User: Hospitals; Oncology Clinics; Rehabilitation Centres; Research Laboratories
Subsegments:
1) By Chemotherapy: Alkylating Agents; Antimetabolites; Combination Therapy
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Intensity-Modulated Radiation Therapy (IMRT); Stereotactic Body Radiation Therapy (SBRT); Proton Therapy
3) By Surgery: Pleurectomy Or Decortication (P/D); Extrapleural Pneumonectomy (EPP); Cytoreductive Surgery; Palliative Surgery
4) By Immunotherapy: Immune Checkpoint Inhibitors; Monoclonal Antibodies; Tumor Vaccines; Adoptive Cell Therapy
5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Angiogenesis Inhibitors; Mesothelin-Targeted Agents; Gene Therapy-Based Approaches
Which Future-Ready Trends Are Expected to Influence the Malignant Mesothelioma Market?
Major companies operating in the malignant mesothelioma market are focusing on developing advanced treatment options, such as monoclonal antibody treatments, to inhibit tumor growth and improve treatment precision. Monoclonal antibodies refer to laboratory-made proteins that mimic the immune system's ability to detect and target specific antigens, such as those found on cancer cells. For instance, in November 2023, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received supplemental approval in Japan for the expanded use of Opdivo (nivolumab), a human anti-human PD-1 monoclonal antibody for the treatment of malignant mesothelioma (excluding malignant pleural mesothelioma). This approval marks Opdivo as a new treatment option for this condition, where no standard treatments were previously established. Opdivo was designated an orphan drug for this indication, highlighting its potential to address a significant medical need.
Who Are the Principal Market Leaders in the Malignant Mesothelioma Market?
Major companies operating in the malignant mesothelioma market are AstraZeneca, NYU Langone Health, Mayo Foundation for Medical Education and Research, The University of Chicago Medical Center, Ono Pharmaceutical Co., Ltd., Dana-Farber Cancer Institute, UVA Health, PharmaMar, Healthcare Global Enterprises Ltd., Fujirebio Europe, Cancer Healer Center, Rosetta Genomics, Mesothelioma UK, The Mesothelioma Center, Oncoplus, Mesothelioma Research Foundation of America, Pleural Mesothelioma Center
Get the detailed malignant mesothelioma market report today
Which Regions Are Expected to Record the Strongest CAGR in the Malignant Mesothelioma Market?
North America was the largest region in the malignant mesothelioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment